Shares of Hims & Hers Health (NYSE: HIMS) experienced a decline this week, falling 9.2% on Tuesday and a total of 12% by Thursday’s close. The drop comes as investors grow concerned about rising competition from major pharmaceutical companies encroaching on the company’s market.
Eli Lilly’s Competitive Move
The primary cause of this week’s stock drop is news from Eli Lilly (NYSE: LLY). On Tuesday, Lilly announced it would offer discounts on single-dose vials of its Zepbound GLP-1 weight loss drug. This decision, driven by high demand, is seen as a strategic move to compete with companies like Hims & Hers Health, which recently launched its own weight loss program featuring GLP-1 drugs.
Increased Competition from Big Pharma
The move by Eli Lilly highlights the growing competition in the direct-to-consumer pharmaceutical market. By offering discounts, Lilly aims to capture market share from competitors, including Hims & Hers. Citigroup has predicted that such competitive actions could significantly impact market share for companies selling similar or off-brand GLP-1 drugs.
Impact on Hims & Hers
Hims & Hers, known for its focus on lifestyle treatments such as antidepressants, weight loss, birth control, and hair loss, has gained traction through strategic advertising and the convenience of home delivery services. Despite a recent 52% increase in revenue, the company’s competitive edge has been questioned.
The discounting of Zepbound by Eli Lilly could pose a threat to Hims & Hers, positioning the company as a less direct player in the market. While the immediate impact of Lilly’s move might not be severe, ongoing competition from major pharmaceutical companies could pose a significant risk to Hims & Hers’ growth prospects.
Looking Ahead
As the pharmaceutical industry continues to evolve, the presence of major players like Eli Lilly in the direct-to-consumer space could present challenges for Hims & Hers. The company will need to navigate this increased competition carefully to maintain its market position and growth trajectory.
